BYNFEZIA Pen (Page 4 of 5)
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility
Studies in laboratory animals have demonstrated no mutagenic potential of octreotide.
No carcinogenic potential was demonstrated in mice treated subcutaneously for 85-99 weeks at doses up to 2,000 mcg/kg/day (8 x the human exposure based on body surface area). In a 116-week subcutaneous study in rats, a 27% and 12% incidence of injection site sarcomas or squamous cell carcinomas was observed in males and females, respectively, at the highest dose level of 1,250 mcg/kg/day (10 x the human exposure based on body surface area) compared to an incidence of 8%-10% in the vehicle-control groups. The increased incidence of injection site tumors was most probably caused by irritation and the high sensitivity of the rat to repeated subcutaneous injections at the same site. Rotating injection sites would prevent chronic irritation in humans. There have been no reports of injection site tumors in patients treated with octreotide for up to 5 years. There was also a 15% incidence of uterine adenocarcinomas in the 1,250 mcg/kg/day females compared to 7% in the saline-control females and 0% in the vehicle-control females. The presence of endometritis coupled with the absence of corpora lutea, the reduction in mammary fibroadenomas, and the presence of uterine dilatation suggest that the uterine tumors were associated with estrogen dominance in the aged female rats which does not occur in humans.
Octreotide did not impair fertility in rats at doses up to 1,000 mcg/kg/day, which represents 7 x the human exposure based on body surface area.
13.2 Animal Toxicology and/or Pharmacology
Reproduction studies have been performed in rats and rabbits at doses up to 16 times the highest recommended human dose based on body surface area and revealed no evidence of harm to the fetus due to octreotide.
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
BYNFEZIA Pen (octreotide acetate) injection, 2,500 mcg/mL octreotide is a clear colorless solution and it is available as:
Dosage Unit | Package Size | NDC # |
2.8 mL single-patient-use prefilled pen | Carton of 1 | NDC 62756-452-36 |
2.8 mL single-patient-use prefilled pen | Carton of 2 | NDC 62756-452-37 |
16.2 Storage and Handling
Store BYNFEZIA Pen in the refrigerator between 2° to 8° C (36° to 46° F) in the carton. Protect the pen from light. After first use store pens at controlled room temperature between 20°C to 25°C (68°F to 77°F). Excursions between 15°C (59°F) and 30°C (86°F) are allowed for up to 28 days. Discard the pen 28 days after first use.
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Instructions for Use).
Cholelithiasis and Complications of Cholelithiasis
Advise patients to contact their healthcare provider if they experience signs or symptoms of gallstones (cholelithiasis) or complications of cholelithiasis (e.g., cholecystitis, cholangitis and pancreatitis) [see Warnings and Precautions (5.1)].
Hypoglycemia and Hyperglycemia
Advise patients to contact their healthcare provider if they have problems with blood sugar levels, either too high (hyperglycemia) or too low (hypoglycaemia) [see Warnings and Precautions (5.2)].
Thyroid Function Abnormalities
Inform patients that their thyroid function will be assessed at baseline and periodically during treatment [see Warnings and Precautions (5.3)].
Cardiac Function Abnormalities
Inform patients to contact the health care provider in case they notice irregular heart beat [see Warnings and Precautions (5.4)].
Decreased Vitamin B12 Levels and Abnormal Schilling’s Tests
Inform patients that Vitamin B12 levels may be monitored during the treatment [see Warnings and Precautions (5.5)].
Pregnancy
Inform female patients that treatment with BYNFEZIA Pen may result in unintended pregnancy [see Use in Specific Populations (8.3)].
Distributed by:
Sun Pharmaceutical Industries, Inc.
Cranbury, NJ 08512
Manufactured by:
Sun Pharmaceutical Industries Ltd.
Halol-Baroda Highway,
Halol-389 350, Gujarat, India
Revised: 04/2020
INSTRUCTIONS FOR USE
INSTRUCTIONS FOR USE
Bynfezia Pen (ben-FEZ-ee-uh PEN)
(octreotide acetate)
Prefilled Pen
Read these instructions before you start using the Bynfezia Pen. It is important that you understand and follow these instructions to use the pen correctly. Bynfezia Pen is a prefilled pen that you or your caregiver can use to give more than 1 dose of medicine.
Ask your healthcare provider about your dose of Bynfezia Pen and how to inject Bynfezia Pen the right way before you inject it for the first time. If your healthcare provider decides that you or your caregiver can give your Bynfezia Pen at home, you or your caregiver should receive training on how to use the pen.
Contact your healthcare provider if you or your caregiver have any questions.
Important | ||
| ||
How should I store my Bynfezia Pen? | ||
Before First Use:
| ||
How do I give a dose larger than 200 mcg (more than 1 injection)? | ||
| ||
Example Dose | Steps to give a total dose larger than 200 mcg | Number of injections needed to give the total dose |
For example, if your total dose is 300 mcg |
| 2 |
For example, if your total dose is 450 mcg |
| 3 |
1. Check the Pen | ||
A. Wash your hands with soap and water (Figure A). | ||
B. Check the expiration (EXP) date (Figure B).
| ||
C. Pull the pen cap straight off the pen (Figure C). | ![]() | |
D. Check the medicine (Figure D).
| ||
E. Allow the pen to reach room temperature.
| ||
2. Attach a Needle | ||
A. Gather the following additional supplies (Figure F):
| ||
B. Wipe the rubber seal on the pen with an alcohol swab (Figure G). | ![]() | |
C. Attach a new needle.
| ![]() ![]() | |
D. Remove the outer needle cover and set it aside (Figure J).
| ![]() | |
E. Remove the inner needle cover and throw it away (Figure K). | ||
Are you using a new pen?
| ||
3. Prime Your Pen | ||
Note: The following steps are only needed if you are using a new pen for the first time or if you drop the pen.To prime the pen, follow the steps below to dial the pen to 100 mcg and press the injection button until a stream of medicine comes from the needle tip.
| ||
A. Turn the dose set knob to dial the pen to 100 mcg (Figure L). | ||
B. Hold the pen with the needle pointing up. | ||
C. Press the injection button all the way in until it stops and the dose display window returns to “0” (Figure M). | ||
D. A stream of medicine should be seen coming from the needle tip (Figure N). If you do not see a stream of medicine coming from the needle tip , repeat the priming steps.If you still do not see a stream of medicine coming from the needle tip after you repeat the priming steps 3 times, the pen may be damaged. Throw away (dispose of) the pen and use a new pen. Call Sun Pharmaceutical Industries, Inc. at 1-800-818-4555 or your healthcare provider for help or to get a new pen. | ![]() | |
4. Prepare the Injection | ||
A. Choose an injection site (see Figure O) for injection under the skin (subcutaneous).
| ||
B. Clean your injection site with an alcohol swab (Figure P).
| ||
C. Dial your dose (Figure Q).
| ||
Note: The pen cannot be dialed past the number of micrograms (mcgs) of medicine left in the pen. If the pen does not have enough medicine to give the full dose, throw away (dispose of) the pen and use a new one. | ||
5. Give the Injection | ||
A. Insert the needle straight into the injection site (Figure R). | ||
B. Deliver your dose.
| ||
C. Continue to hold the injection button down and slowly count to 10 to make sure the full dose of medicine is given (Figure T). | ||
D. Remove the pen from the injection site.
| ||
6. After the Injection | ||
A. Carefully place the outer needle cover back onto the needle.
| ||
B. Unscrew and remove the covered needle (Figure W).
| ||
C. Throw away (dispose of) the covered needle in a FDA-cleared sharps container (Figure X). | ||
D. Put the pen cap back on the pen (Figure Y) and store the pen.
| ||
E. Treat the injection site.
| ||
Cleaning the Pen | ||
| ||
Additional Disposal Information | ||
Put used pens and needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) pens and needles in the household trash. If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
|
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Distributed by:
Sun Pharmaceutical Industries, Inc.
Cranbury, NJ 08512
Manufactured by:
Sun Pharmaceutical Industries Ltd.
Halol-Baroda Highway,
Halol-389 350, Gujarat, India
For more information, call 1-800-818-4555.
Issued: 04/2020
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.